Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. - Wikidata - wikimedia - TriplyDB

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.

http://www.wikidata.org/entity/Q30275582

about

Nonmyeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenstrom macroglobulinemia: Evidence for a graft-versus-lymphoma effect.

P2860

Q54419189-FCC8FF6E-0BB5-43C5-9831-05A2360701F3

P2860

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.

http://www.wikidata.org/entity/Q30275582

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Allogeneic Transplantation for ...... nd Lymphoplasmacytic Lymphoma.

@ast

Allogeneic Transplantation for ...... nd Lymphoplasmacytic Lymphoma.

@en

type

label

Allogeneic Transplantation for ...... nd Lymphoplasmacytic Lymphoma.

@ast

Allogeneic Transplantation for ...... nd Lymphoplasmacytic Lymphoma.

@en

prefLabel

Allogeneic Transplantation for ...... nd Lymphoplasmacytic Lymphoma.

@ast

Allogeneic Transplantation for ...... nd Lymphoplasmacytic Lymphoma.

@en

P1433

Q30275582-D27283D7-3A4A-4463-BA8C-EC45296F51BB

P1476

Q30275582-254D2D69-3279-4A85-A4A4-99E9E537E9FD

P2093

Q30275582-017CCE3D-8F3C-4623-9E8E-11472E88E85D

Q30275582-14AF28D4-191B-4508-A2D5-E7A99D575F9F

Q30275582-1A49A50D-238E-47EF-9B9F-8CFD19C3305E

Q30275582-1F507D69-A686-41E9-93AC-C9AA804B6B5F

Q30275582-2935A334-D285-4FD5-8B2B-3EA38D24CCFB

Q30275582-2BE55380-2E7E-4066-8320-3C41512E7EE4

Q30275582-3F98ED87-ABAD-4CFB-BCB3-DCFBCDD1C939

Q30275582-477457A4-1C39-413B-A3CF-240E58FCE5DF

Q30275582-5F1D45BA-01E4-4766-A0D2-1E3596D96A5B

Q30275582-7648B324-07D8-4746-8EC4-50F5CD53E762

P2860

Q30275582-1B1F79EE-3091-4BD3-BA55-585637A45E57

Q30275582-2E3B6D64-E99B-4D3B-8C58-627FE15FED81

Q30275582-3B1049FF-D8C1-4BB8-82FB-8B2ED4FCBD81

Q30275582-40D5D71B-6855-4089-98B5-C2E5704AB287

Q30275582-571B40E7-FA10-44AB-A796-698CC6BEEF21

Q30275582-73C68357-F7EC-4875-851E-8D36E1D30AC5

Q30275582-7830818B-BC25-4710-AB6E-F29BACCEE410

Q30275582-7B70E761-6D0E-41D4-B27D-C17BA24FE38D

Q30275582-7C3848E7-1B76-4610-8AE8-6577A7D64A28

Q30275582-9254CD2E-47E3-465D-9D9E-A268876AC2E7

P304

Q30275582-913DB305-8842-4DCC-AAB7-EA3F02A81D4F

P31

Q30275582-6620D982-EE15-4B2A-8B88-7117BD014102

P356

Q30275582-E702E39D-AC40-4269-A707-8A1F68E8FD8D

P433

Q30275582-EC652403-D9D6-4942-BF30-65459842A724

P478

Q30275582-6E360D4F-CC7D-4B90-8F23-1B8C239FD4D5

P50

Q30275582-1326754F-1A25-483F-94E4-D687FACE18CD

Q30275582-429CD834-D0C8-422C-A834-71454294393F

Q30275582-54EFC7F8-AAED-45E9-BCE5-4DF8B3F460D7

Q30275582-74C86719-5A90-4882-816F-5E4817DAEB3B

Q30275582-FA39BFDA-7EF7-4F4A-AD5D-E2D36244E29A

P577

Q30275582-0C7F5DDE-4CB2-4B7F-9CF1-3578C5B089B8

P698

Q30275582-F1AEEA09-FFF1-4AD9-B866-1D90DEE0C93F

P932

Q30275582-8CA0DFD2-8492-4057-A2F5-2353C03F002C

P356

J.BBMT.2016.10.010

P1433

Biology of Blood and Marrow Transplantation

P1476

Allogeneic Transplantation for ...... nd Lymphoplasmacytic Lymphoma.

@en

P2093

A Samer Al-Homsi

http://www.w3.org/2001/XMLSchema#string

Anita D'Souza

http://www.w3.org/2001/XMLSchema#string

Cesar O Freytes

http://www.w3.org/2001/XMLSchema#string

David H Vesole

http://www.w3.org/2001/XMLSchema#string

David I Marks

http://www.w3.org/2001/XMLSchema#string

Edward Copelan

http://www.w3.org/2001/XMLSchema#string

Gerhard Hildebrandt

http://www.w3.org/2001/XMLSchema#string

Jean Yared

http://www.w3.org/2001/XMLSchema#string

Jiaxing Huang

http://www.w3.org/2001/XMLSchema#string

Kwang Woo-Ahn

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the intensity of conditioning regimens: working definitions

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients

Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia

Transplantation in Waldenstrom's macroglobulinemia--the French experience

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens

Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

P304

60-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2016.10.010

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Robert Peter Gale

Parameswaran Hari

Hillard M Lazarus

P577

2016-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27789362

http://www.w3.org/2001/XMLSchema#string

P932

5182098

http://www.w3.org/2001/XMLSchema#string